{"id":"W3207677309","doi":"10.1097/qad.0000000000003085","title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Rilpivirine; Dosing; Medicine; Dolutegravir; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Clinical endpoint; Clinical trial; Virology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001051615,0.0002873967,0.0006949612,0.0001982944,0.0003935508,0.0004623699,0.0003376912,0.0005715,0.005400516],"category_scores_gemma":[0.001006028,0.0001356097,0.0004428952,0.0001649953,0.0001645205,0.0003802789,0.0002085774,0.0007175024,0.0007155405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003497245,"about_ca_system_score_gemma":0.0005335372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008082989,"about_ca_topic_score_gemma":0.002049921,"domain_scores_codex":[0.9996517,0.00009664729,0.00003962068,0.00007114177,0.00006094718,0.00008003139],"domain_scores_gemma":[0.9997285,0.00007073548,0.00006259064,0.00002545936,0.00002042962,0.00009235919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.199049,0.02828953,0.0879009,0.0006665211,0.0006810964,0.001530364,0.0008199014,0.001259464,0.05102337,0.0005209717,0.006237305,0.6220216],"study_design_scores_gemma":[0.1749091,0.3376687,0.4177053,0.0005012346,0.001130046,0.005108151,0.000596918,0.005257151,0.02070307,0.0008038118,0.03548815,0.0001283239],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945749,0.000840791,0.0005064411,0.00019029,0.00004781041,0.0007517639,0.0002879105,0.00007107518,0.002728902],"genre_scores_gemma":[0.9959899,0.000270432,0.0008398399,0.0004216773,0.00004902281,0.0005374611,0.0004893976,0.00000823407,0.001394089],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005400516,"threshold_uncertainty_score":0.01806653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0185377159993329,"score_gpt":0.2898791553787556,"score_spread":0.2713414393794227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}